The randomized and placebo-controlled phase 2 SORMAIN trial showed improved relapse-free survival (RFS) in AML patients with FLT3-ITD mutations when sorafenib was applied as maintenance therapy after ASCT. The gene discussed is FLT3; the disease is acute myeloid leukemia.